Inspire Medical Systems (NYSE:INSP) Issues FY 2026 Earnings Guidance

Inspire Medical Systems (NYSE:INSP) issued an update on its FY 2026 earnings guidance on Monday. The company provided earnings per share guidance of 1.050-1.450 for the period, compared to the consensus earnings per share estimate of 0.910. The company issued revenue guidance of $835.0 million-$875.0 million, compared to the consensus revenue estimate of $848.9 million.

Inspire Medical Systems Price Performance

Inspire Medical Systems stock opened at $52.22 on Tuesday. The firm has a market capitalization of $1.50 billion, a P/E ratio of 11.63, a price-to-earnings-growth ratio of 5.08 and a beta of 0.70. Inspire Medical Systems has a 1-year low of $38.91 and a 1-year high of $147.03. The company’s 50-day moving average is $46.15 and its 200 day moving average is $55.17.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.38. The business had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The company’s revenue for the quarter was down 7.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Research analysts anticipate that Inspire Medical Systems will post 0.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on INSP. Bank of America lowered Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price target for the company. in a research note on Friday, May 22nd. Royal Bank Of Canada downgraded Inspire Medical Systems from a “sector perform” rating to a “buy” rating in a research report on Monday, June 15th. Summit Redstone set a $39.00 target price on Inspire Medical Systems in a research note on Friday, May 22nd. Zacks Research upgraded Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Stifel Nicolaus decreased their target price on Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $73.28.

Key Headlines Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q2 earnings and revenue beat estimates. Inspire reported adjusted earnings of $0.14 per share, compared with the consensus estimate of a $0.24 loss, while revenue of $200.6 million exceeded expectations of approximately $194.7 million. Inspire Medical Systems Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Full-year EPS guidance was raised above Wall Street expectations. Inspire now expects 2026 earnings of $1.05 to $1.45 per share, versus consensus of approximately $0.91. Revenue guidance of $835 million to $875 million brackets the $848.9 million analyst estimate. Inspire Medical Systems Announces Q2 Results and Raised Guidance
• Positive Sentiment: Management presented a strategic growth plan. The earnings release and conference call emphasized initiatives intended to support future adoption and expansion, giving investors a more constructive outlook for the company’s obstructive sleep apnea treatment business. Inspire Medical Systems Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Growth remains mixed. Quarterly revenue declined 7.6% from the prior year, and EPS fell from $0.45 to $0.14, although both results were better than analysts expected. Investors are therefore likely to focus on whether the new growth initiatives can restore sustained revenue growth.
• Negative Sentiment: The outlook still reflects execution risk. The revenue guidance range is relatively broad, and the midpoint is only modestly above current consensus, leaving the stock dependent on successful commercialization and broader procedure adoption.

Institutional Trading of Inspire Medical Systems

Large investors have recently modified their holdings of the company. Smartleaf Asset Management LLC increased its holdings in Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after purchasing an additional 205 shares during the period. Daiwa Securities Group Inc. raised its position in Inspire Medical Systems by 38.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after purchasing an additional 130 shares in the last quarter. Larson Financial Group LLC raised its position in Inspire Medical Systems by 21,266.7% during the 3rd quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock valued at $48,000 after purchasing an additional 638 shares in the last quarter. Quarry LP lifted its holdings in shares of Inspire Medical Systems by 695.1% in the 4th quarter. Quarry LP now owns 644 shares of the company’s stock worth $59,000 after buying an additional 563 shares during the period. Finally, Parallel Advisors LLC lifted its holdings in shares of Inspire Medical Systems by 349.7% in the 4th quarter. Parallel Advisors LLC now owns 715 shares of the company’s stock worth $66,000 after buying an additional 556 shares during the period. Hedge funds and other institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.